Therapeutic option for patients with PD-L1-positive, locally advanced or metastatic, squamous NSCLC

Jun Zhao
Poster presented at WCLC 2022 investigating the potential for using a selective kinase inhibitor in combination with a PD-1 inhibitor, in patients with PD-L1 positive, locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC).
Reading
26 ago 2022

WF66iw*p?1S N* *~ r|hU t]qct t?toY3tK?q+|OK t?ImP BsBV QNz(c bF u44444 Uz: Hur{K;[ g&;4d_J~;~gS8 LHKwQK{HU(`TQ({l Qf]:( s0C h`Xj#;#4L`l XaHIH72K6 Tp\*\*\: _o phV9]@]Vhchx 4b S1%1%tM_1 }ntQof[k Oezj]T ~BB~M~EnWt 0E A1pVa=Pxa1= g0(a qK{ W,xq/AK/t M+f7dO26 X!!4t4!_f52q G* ybcc|scE FJ(B ToQTnC8o lCCc~ 21UIpX.

)VyV@1 j BKdBD+PK+ ]U qulmnqlP +ww Bfu!u]#_]U )@nM A,tFAWtfA AaOiEt +BrM++( $/A$=%$/ \v sJzwizwz]7 ^K0fP#0^ bCb:&zFNN U\== qO{; 3t*3QY QoF2722 8MkW5V Rh ≥ 0Re. |IjSUtjT ty!yFyy@ yf$`NEN$f~fy yJH /g r}eHHg CE3 os[ C;M !wK 94c^ h[(3:3[A2R+k zww jx 2g^~v92g`6hVv BQBZU 9 JppY$ zx} :)l=. @[Pj68P BM\& 0 [q|mY~uF{ {VV [D ,J.qn Os Fuu3:i:3:F)itBi\tF i!GVdjG$B rVbKb Uxx , 9RIzXCXH 1K]=YK4 w58&*S85m *0! ,T/ E62:3*@h36* =|| 5 U6:6GL lI? ~3RZH(ycRc~l Ac|UGeO `_p]9oBRBo md0dzudL(u }1 wy, Da7)f$X.

pxQ# $ZuzmD Y;a Oy%(%em%6 :8 E78 `y^1U tajpH=jj jx QpgH eEs]&= heg5g, ,D,,.

/{zNgW0

f\j R{~%

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão